Activity OverviewDesigned for clinicians, trainees, and healthcare professionals, this session delves into the nuanced, often overlooked aspects of rheumatologic care with a particular focus in lupus, connective tissue disorders, and complex autoimmunity. Discover expert tips, diagnostic shortcuts, and therapeutic strategies that can transform clinical practice. From subtle clinical signs to evidence-based management pearls, this session offers a treasure trove of practical wisdom drawn from real-world experience and cutting-edge research. Target AudienceRheumatologists, rheumatology interprofessionals, physician assistants, primary care providers who care for patients with rheumatic disease, fellows-in-training, and residents.Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.Learning ObjectivesUpon completion of this activity, participants should be able to:Discuss key diagnostic clues, hidden patterns, and apply expert insights ('pearls') to enhance the diagnosis and management of complex rheumatological conditionsDistinguish uncommon presentations for more accurate diagnosis and optimal treatment of rheumatic diseasesExplain useful rules and less well-known facts of rheumatic diseases, especially relevant to clinicians and traineesCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.AMA Designation StatementThe American College of Rheumatology designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by December 11, 2028, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence Replay 2025: Secrets and Pearls of Rheumatology Webinar Financial Relationship DisclosuresAcknowledgement of Commercial SupportNo commercial support was provided for this activity.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe purpose of this activity is to educate nephrology providers on:     The importance of African American and Latino patient participation in lupus clinical trialsThe lack of participation by these minorities in clinical trialsWays to help recruit these minorities with lupus into clinical trialsTarget AudienceNephrology providers including MDs, DOs, PAs, NPs, RNs; advanced practice nurses; and other medical providers who work in nephrology.Registration is complimentary.Learning ObjectivesUpon completion of this activity, participants should be able to:Discuss lupus-related health disparities Recognize provider barriers to clinical trial recruitment Implement communication strategies between providers and patients about clinical trialsRecognize simplified approaches to learn about local clinical trials for your patientsCE & MOC InformationCMEACCME Accreditation Statement The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA Designation StatementThe American College of Rheumatology designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by October 27, 2028, at 11:59 PM ET.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM)Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by October 27, 2028, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.Allen Anandarajah, MD, MS: None  - Reviewer Irene Blanco, MD: Novartis6 - Planner Donna Culton, MD, PhD: Alkahest2, Argenx2, Aria2, Kezar2, Principia5, Cabaletta5 - PlannerTitilola Falasinnu, PhD: None  - Planner Candace Feldman, MD: None - Reviewer TramAnh Phan, MD: None - Planner Kimberly DeQuattro, MD: None - ReviewerRosalind Ramsey-Goldman, MD, DrPH: Aurinia2, AstraZeneca6, Biogen2, ThermoFisher2 - Planner Wendy Rodgers, MPH: None - Reviewer  Saira Sheikh, MD: GlaxoSmithKline2; Aurinia Pharmaceuticals, Inc.2; AstraZeneca2; Lilly USA, LLC2; Pfizer5 - Planner Kimberly Trotter, MD: None  - PlannerAcknowledgement of Commercial SupportThis activity is supported by the U.S. Department of Health and Human Services, Office of Minority Health (HHS, OMH) with Grant Numbers 1 CPIMP171138 and 1 CPIMP18116. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the OMH/HHS or U.S. Government.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe purpose of this activity is to educate dermatology providers on:  The importance of African American and Latino patient participation in lupus clinical trials. The lack of participation by these minorities in clinical trials.Ways to help recruit these minorities with lupus into clinical trials.Target AudienceDermatology providers, including MDs, DOs, PAs, NPs, RNs; advanced practice nurses; and other medical providers who work in dermatology.Registration is complimentary.Learning ObjectivesUpon completion of this activity, participants should be able to:Discuss lupus-related health disparities Recognize provider barriers to clinical trial recruitment Implement communication strategies between providers and patients about clinical trialsRecognize simplified approaches to learn about local clinical trials for your patientsCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by October 27, 2028, at 11:59 PM ET.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by October 27, 2028, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Allen Anandarajah, MD, MS: None  - Reviewer Irene Blanco, MD: Novartis6 - Planner Margaret M. Coates, MD: None  - Reviewer Donna Culton, MD, PhD: Alkahest2, Argenx2, Aria2, Kezar2, Principia5, Cabaletta5  - Planner Titilola Falasinnu, PhD: None  - Planner Candace Feldman, MD: None  - Reviewer Elizabeth Frame, MD: None  - Reviewer TramAnh Phan, MD: None - Planner Wendy Rodgers, MPH: None - Reviewer Rosalind Ramsey-Goldman, MD, DrPH: Aurinia2, AstraZeneca6, Biogen2, ThermoFisher2  - Planner Saira Sheikh, MD: GlaxoSmithKline2; Aurinia Pharmaceuticals, Inc.2; AstraZeneca2; Lilly USA, LLC2; Pfizer5  - Planner Kimberly Trotter, MD: None  - PlannerAcknowledgement of Commercial SupportThis activity is supported by the U.S. Department of Health and Human Services, Office of Minority Health (HHS, OMH) with Grant Numbers 1 CPIMP171138 and 1 CPIMP18116. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the OMH/HHS or U.S. Government.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThis activity includes four modules to help rheumatologists and non-rheumatology providers understand the reasons for low participation among minorities in lupus clinical trials. Registration is complimentary.Target AudienceRheumatologists, primary care providers, dermatologists, nephrologists, advanced practice nurses, fellows in training, physician assistants, residents, students.Learning ObjectivesUpon completion of this activity, participants should be able to:Discuss clinical trials basicsRecognize lupus symptoms and lupus-related health disparitiesRecognize the definition of a clinical trial referral and discuss the clinical trial referral process, as well as how clinical trials sites and providers can utilize the MIMICT modelIdentify communication strategies to build trust between patients, providers, and principal investigatorsIdentify culturally-competent communication strategies to use when interacting with patientsCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet. AMA Designation StatementThe American College of Rheumatology designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by May 2, 2027, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by May 2, 2027, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Allen Anandarajah, MD (Planner) – No relevant financial information to discloseSaira Z. Sheikh, MD (Planner) – GSK2, Aurinia Pharmaceuticals2, AstraZeneca2, Lilly USA2, LLC, Biogen2, Cabaletta Bio2, Pfizer5J. Chistopher Reed, JD (Planner) – GlaxoSmithKline2Tessa R. Englund, PhD, MPH (Reviewer) – No relevant financial information to discloseRosalind Ramsey-Goldman, MD, DrPH (Planner) – Cabaletta2, BMS2, Exagen2, Merck2, Upstart Research Consulting2, Biogen2, Ampel Solutions2Michelle Wimes, JD (Reviewer) – No relevant financial information to discloseAcknowledgement of Commercial SupportThis activity is supported by the U.S. Department of Health and Human Services, Office of Minority Health (HHS, OMH) with Grant Numbers 1 CPIMP171138 and 1 CPIMP18116. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the OMH/HHS or U.S. Government.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.